ScreenHER

Developing a high-sensitivity, point-of-care diagnostic platform for cervical precancer and cancer screening.

Cover Block
Name ScreenHER
Tagline Developing a high-sensitivity, point-of-care diagnostic platform for cervical precancer and cancer screening.
Headquarters Cincinnati, United States
Stage Pre-Seed
Business Model Hardware + Software
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale

Links

The Short Version

ScreenHER is an early-stage healthtech startup developing a point-of-care diagnostic platform for cervical precancer and cancer screening. The company's core product is a high-sensitivity, rapid-format test designed for clinical or community health settings, aiming to improve early detection. This positioning suggests a wedge strategy targeting low-resource or under-screened populations. The company is likely in a pre-seed, stealth phase of development.

Data Accuracy: YELLOW -- Product claims are based on the company's own description; team and funding details are absent from public sources.

Taxonomy Snapshot

Axis Value
Stage Pre-Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale

The Company in Brief

ScreenHER is an early-stage women's health diagnostics company based in Cincinnati, Ohio, focused on point-of-care cervical cancer screening. The company's public presence is minimal, with its founding story, leadership, and corporate milestones not yet disclosed in mainstream press or regulatory filings. Its primary description is that of a developer of a high-sensitivity, point-of-care diagnostic platform for cervical precancer and cancer.

Data Accuracy: YELLOW -- Company claims are sourced from its own site and LinkedIn; no independent public corroboration for founding details or milestones exists.

What They Have Built

ScreenHER's public product definition is a high-level promise. The company describes its work as developing a "high-sensitivity, point-of-care diagnostic platform" designed to identify cervical precancerous and cancer signals in a simple, rapid format. This positioning frames the product as a tool for clinical or near-patient settings, such as an OB-GYN office or a community health clinic.

Data Accuracy: YELLOW -- Product claims are sourced solely from the company's own description; no independent technical validation or detailed specifications are available.

Market Size and Demand

Cervical cancer remains a preventable disease where early detection is critical. According to the World Health Organization, cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020 [WHO, 2023]. In the United States, the CDC reports over 14,000 new cases of cervical cancer diagnosed each year [CDC, 2023]. The global cervical cancer diagnostics market was valued at $6.8 billion in 2022 and is projected to grow at a compound annual rate of approximately 5% through 2030 [Grand View Research, 2023]. The broader point-of-care diagnostics market is valued at over $40 billion globally [Kalorama Information, 2023].

Metric Value
Global Cervical Cancer Diagnostics Market (2022) 6.8 $B
Projected CAGR (2023-2030) 5 %
Global Point-of-Care Diagnostics Market 40 $B

Data Accuracy: YELLOW -- Market sizing figures are drawn from third-party industry reports and public health agency statistics.

Who Else Is Fighting for This

ScreenHER’s competitive position is defined by its ambition to insert a rapid, point-of-care device into a cervical cancer screening workflow historically dominated by centralized laboratory services. Incumbent laboratory-based cytology and molecular HPV tests, offered by firms like Roche and Hologic, represent the standard of care. ScreenHER’s proposed edge rests on the combination of high sensitivity and point-of-care speed, a wedge into low-resource and under-screened populations.

Data Accuracy: YELLOW -- Competitive map is inferred from company positioning and general market knowledge; no direct competitors are named in available sources.

Opportunity

ScreenHER's opportunity rests on becoming the standard of care for cervical cancer screening in clinical settings where access to advanced laboratory infrastructure is limited. If the technology delivers lab-grade accuracy in a rapid, clinic-room format, it could shift the screening workflow from a multi-visit process to a single-visit diagnosis.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated mission and the well-documented structural gaps in global cervical cancer screening.

Sources

Articles about ScreenHER

Related companies

Topics

View on Startuply.vc